# Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

> **NCT05516407** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fenix Innovation Group** · enrollment: 18 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** FEN164

## Key facts

- **NCT ID:** NCT05516407
- **Lead sponsor:** Fenix Innovation Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-08-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05516407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05516407, "Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05516407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*